Richard D. Egleton

4.9k total citations · 1 hit paper
52 papers, 3.9k citations indexed

About

Richard D. Egleton is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Richard D. Egleton has authored 52 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 22 papers in Oncology and 21 papers in Neurology. Recurrent topics in Richard D. Egleton's work include Barrier Structure and Function Studies (21 papers), Drug Transport and Resistance Mechanisms (20 papers) and Neuropeptides and Animal Physiology (15 papers). Richard D. Egleton is often cited by papers focused on Barrier Structure and Function Studies (21 papers), Drug Transport and Resistance Mechanisms (20 papers) and Neuropeptides and Animal Physiology (15 papers). Richard D. Egleton collaborates with scholars based in United States. Richard D. Egleton's co-authors include Thomas P. Davis, Jason D. Huber, Brian T. Hawkins, Kathleen C. Brown, Piyali Dasgupta, K. Witt, Rachel C. Brown, Karen S. Mark, Tracy A. Brooks and Heddwen L. Brooks and has published in prestigious journals such as Journal of the American Chemical Society, Trends in Neurosciences and Diabetes.

In The Last Decade

Richard D. Egleton

52 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier

2001 631 citations Jason D. Huber, Richard D. Egleton et al. Trends in Neurosciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard D. Egleton United States	33	1.8k	1.5k	728	653	546	52	3.9k
Carola Y. Förster Germany	33	1.6k 0.9×	1.6k 1.1×	295 0.4×	673 1.0×	410 0.8×	110	4.4k
Siti R. Yusof Malaysia	13	1.3k 0.7×	1.7k 1.2×	446 0.6×	669 1.0×	492 0.9×	26	4.2k
Marie‐Pierre Dehouck France	34	1.7k 0.9×	1.9k 1.3×	487 0.7×	1.4k 2.1×	545 1.0×	58	4.9k
Diana E. M. Dolman United Kingdom	10	1.4k 0.8×	1.8k 1.2×	498 0.7×	705 1.1×	515 0.9×	15	4.4k
Ingolf E. Blasig Germany	48	3.2k 1.8×	3.6k 2.5×	467 0.6×	746 1.1×	1.1k 1.9×	132	7.2k
Adjanie Patabendige United Kingdom	12	1.4k 0.8×	1.9k 1.3×	621 0.9×	740 1.1×	521 1.0×	26	4.6k
Laurence Fénart France	39	1.9k 1.1×	1.5k 1.0×	413 0.6×	1.4k 2.1×	848 1.6×	64	5.1k
Jean‐François Ghersi‐Egea France	38	1.2k 0.7×	1.1k 0.8×	947 1.3×	1.0k 1.6×	595 1.1×	93	4.8k
Jason D. Huber United States	40	1.8k 1.0×	1.8k 1.2×	823 1.1×	505 0.8×	718 1.3×	92	5.0k
Jia Lu Singapore	32	1.5k 0.8×	953 0.7×	278 0.4×	175 0.3×	355 0.7×	65	3.5k

Countries citing papers authored by Richard D. Egleton

Since Specialization

Citations

This map shows the geographic impact of Richard D. Egleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard D. Egleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard D. Egleton more than expected).

Fields of papers citing papers by Richard D. Egleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard D. Egleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard D. Egleton. The network helps show where Richard D. Egleton may publish in the future.

Co-authorship network of co-authors of Richard D. Egleton

This figure shows the co-authorship network connecting the top 25 collaborators of Richard D. Egleton. A scholar is included among the top collaborators of Richard D. Egleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard D. Egleton. Richard D. Egleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davis, Thomas P., Thomas J. Abbruscato, & Richard D. Egleton. (2015). Peptides at the blood brain barrier: Knowing me knowing you. Peptides. 72. 50–56. 6 indexed citations

Egleton, Richard D. & Thomas J. Abbruscato. (2014). Drug Abuse and the Neurovascular Unit. Advances in pharmacology. 71. 451–480. 10 indexed citations

Campos, Christopher, Scott M. Ocheltree, Sharon Hom, Richard D. Egleton, & Thomas P. Davis. (2008). Nociceptive inhibition prevents inflammatory pain induced changes in the blood–brain barrier. Brain Research. 1221. 6–13. 32 indexed citations

Egleton, Richard D., Kathleen C. Brown, & Piyali Dasgupta. (2008). Angiogenic activity of nicotinic acetylcholine receptors: Implications in tobacco-related vascular diseases. Pharmacology & Therapeutics. 121(2). 205–223. 72 indexed citations

Egleton, Richard D., Kathleen C. Brown, & Piyali Dasgupta. (2008). Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends in Pharmacological Sciences. 29(3). 151–158. 221 indexed citations

Hom, Sharon, Melissa A. Fleegal, Richard D. Egleton, et al.. (2007). Comparative changes in the blood-brain barrier and cerebral infarction of SHR and WKY rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 292(5). R1881–R1892. 56 indexed citations

Hawkins, Brian T. & Richard D. Egleton. (2007). Pathophysiology of the Blood–Brain Barrier: Animal Models and Methods. Current topics in developmental biology. 80. 277–309. 70 indexed citations

Hawkins, Brian T., et al.. (2006). Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 50(1). 202–211. 287 indexed citations

Brooks, Tracy A., Scott M. Ocheltree, Melissa J. Seelbach, et al.. (2006). Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Research. 1120(1). 172–182. 46 indexed citations

10.

Hawkins, Brian T. & Richard D. Egleton. (2005). Fluorescence imaging of blood–brain barrier disruption. Journal of Neuroscience Methods. 151(2). 262–267. 115 indexed citations

11.

Huber, Jason D., Richard D. Egleton, K. Witt, et al.. (2003). Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile. Journal of Pharmaceutical Sciences. 92(7). 1377–1385. 11 indexed citations

12.

Witt, K., Jason D. Huber, Richard D. Egleton, & Thomas P. Davis. (2002). Pluronic P85 Block Copolymer Enhances Opioid Peptide Analgesia. Journal of Pharmacology and Experimental Therapeutics. 303(2). 760–767. 22 indexed citations

13.

Huber, Jason D., Richard D. Egleton, & Thomas P. Davis. (2001). Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier. Trends in Neurosciences. 24(12). 719–725. 631 indexed citations breakdown →

14.

Egleton, Richard D., Scott A. Mitchell, Jason D. Huber, et al.. (2001). Improved Blood-Brain Barrier Penetration and Enhanced Analgesia of an Opioid Peptide by Glycosylation. Journal of Pharmacology and Experimental Therapeutics. 299(3). 967–972. 75 indexed citations

15.

Witt, K., Terrence J. Gillespie, Jason D. Huber, Richard D. Egleton, & Thomas P. Davis. (2001). Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides. 22(12). 2329–2343. 175 indexed citations

16.

Witt, K., Cheryl A. Slate, Richard D. Egleton, et al.. (2000). Assessment of Stereoselectivity of Trimethylphenylalanine Analogues of δ‐Opioid [D‐Pen²,D‐Pen⁵]‐Enkephalin. Journal of Neurochemistry. 75(1). 424–435. 32 indexed citations

17.

Witt, K., Jason D. Huber, Richard D. Egleton, & Thomas P. Davis. (2000). Insulin Enhancement of Opioid Peptide Transport across the Blood-Brain Barrier and Assessment of Analgesic Effect. Journal of Pharmacology and Experimental Therapeutics. 295(3). 972–978. 14 indexed citations

18.

Egleton, Richard D. & Thomas P. Davis. (1999). Transport of the δ-opioid receptor agonist [D-penicillamine2,5] enkephalin across the blood–brain barrier involves transcytosis1. Journal of Pharmaceutical Sciences. 88(4). 392–397. 23 indexed citations

19.

Gentry, Cynthia L., et al.. (1999). The effect of halogenation on blood–brain barrier permeability of a novel peptide drug☆. Peptides. 20(10). 1229–1238. 113 indexed citations

20.

Egleton, Richard D., Sarah Thomas, & Thomas P. Davis. (1998). Transport of Opioid Peptides into the Central Nervous System. Journal of Pharmaceutical Sciences. 87(11). 1433–1439. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact